- Home
- EDTK vs PULM Comparison
EDTK vs PULM Comparison
Compare EDTK & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- PULM
- Stock Information
- Founded
- EDTK 2013
- PULM 2003
- Country
- EDTK China
- PULM United States
- Employees
- EDTK 28
- PULM N/A
- Industry
- EDTK Other Consumer Services
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- PULM Health Care
- Exchange
- EDTK Nasdaq
- PULM Nasdaq
- Market Cap
- EDTK 17.7M
- PULM 18.3M
- IPO Year
- EDTK 2020
- PULM N/A
- Fundamental
- Price
- EDTK $1.06
- PULM $4.58
- Analyst Decision
- EDTK
- PULM
- Analyst Count
- EDTK 0
- PULM 0
- Target Price
- EDTK N/A
- PULM N/A
- AVG Volume (30 Days)
- EDTK 11.0K
- PULM 11.8K
- Earning Date
- EDTK 08-08-2025
- PULM 11-07-2025
- Dividend Yield
- EDTK N/A
- PULM N/A
- EPS Growth
- EDTK N/A
- PULM N/A
- EPS
- EDTK N/A
- PULM N/A
- Revenue
- EDTK $893,690.00
- PULM $369,000.00
- Revenue This Year
- EDTK N/A
- PULM N/A
- Revenue Next Year
- EDTK N/A
- PULM $134.88
- P/E Ratio
- EDTK N/A
- PULM N/A
- Revenue Growth
- EDTK N/A
- PULM N/A
- 52 Week Low
- EDTK $0.80
- PULM $1.96
- 52 Week High
- EDTK $1.20
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- EDTK 48.86
- PULM 42.24
- Support Level
- EDTK $1.07
- PULM $4.83
- Resistance Level
- EDTK $1.14
- PULM $5.50
- Average True Range (ATR)
- EDTK 0.04
- PULM 0.25
- MACD
- EDTK -0.00
- PULM 0.02
- Stochastic Oscillator
- EDTK 20.00
- PULM 23.97
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).